MedPath
Found 9 clinical trials|View Analysis
Sort by:

Clinical Study of ARD103 CAR-T Therapy for Patients with R/R AML or MDS

Phase 1
Not yet recruiting
Conditions
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
MDS (Myelodysplastic Syndrome)
Interventions
First Posted Date
2024-11-08
Last Posted Date
2024-11-08
Lead Sponsor
ARCE Therapeutics, Inc.
Target Recruit Count
49
Registration Number
NCT06680752

Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care

Recruiting
Conditions
MDS (Myelodysplastic Syndrome)
First Posted Date
2019-12-27
Last Posted Date
2024-02-22
Lead Sponsor
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Target Recruit Count
1000
Registration Number
NCT04212390
Locations
🇮🇹

IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy

🇮🇹

Elena Crisà, Candiolo, Torino, Italy

Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

Phase 1
Terminated
Conditions
AML - Acute Myeloid Leukemia
MDS (Myelodysplastic Syndrome)
NHL - Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
ALL
Mixed Phenotype Acute Leukemia
Interventions
Biological: T-allo10
First Posted Date
2017-06-26
Last Posted Date
2024-07-18
Lead Sponsor
Roncarolo, Maria Grazia, MD
Target Recruit Count
5
Registration Number
NCT03198234
Locations
🇺🇸

Lucile Packard Children's Hospital, Palo Alto, California, United States

Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Phase 1
Terminated
Conditions
MDS (Myelodysplastic Syndrome)
Chronic Lymphocytic Leukemia
AML (Acute Myelogenous Leukemia)
CML (Chronic Myelogenous Leukemia)
Acute Lymphoblastic Leukemia
Interventions
Biological: MVST
Biological: MVSTr
First Posted Date
2014-09-04
Last Posted Date
2019-12-17
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
12
Registration Number
NCT02231853
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

Phase 1
Terminated
Conditions
MDS (Myelodysplastic Syndrome)
Interventions
Drug: INCB047986
First Posted Date
2014-03-21
Last Posted Date
2018-01-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
6
Registration Number
NCT02093429

Preventing Stem Cell Transplant Complications With a Blood Separator Machine

Phase 1
Completed
Conditions
Lymphoma, Non-Hodgkin
AML (Acute Myelogenous Leukemia
Myeloproliferative Disorder
MDS (Myelodysplastic Syndrome)
ALL (Acute B-Lymphoblastic Leukemia)
Interventions
Device: Graft Manipulation (CD34+ Selection)
First Posted Date
2013-06-03
Last Posted Date
2020-07-21
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
41
Registration Number
NCT01866839
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

Phase 2
Recruiting
Conditions
MDS (Myelodysplastic Syndrome)
Severe Aplastic Anemia
Interventions
Device: Miltenyi CD34 Reagent System
Other: Donor derived G-CSF mobilized PBC
First Posted Date
2010-08-03
Last Posted Date
2025-01-07
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
120
Registration Number
NCT01174108
Locations
🇺🇸

University of Maryland, Baltimore (UMB), Baltimore, Maryland, United States

🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of Azacitidine, and Thalidomide in Higher Risk MDS (Myelodysplastic Syndrome)

Phase 2
Conditions
Myelodysplastic Syndrome
First Posted Date
2008-06-25
Last Posted Date
2008-06-25
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
50
Registration Number
NCT00704704
Locations
🇮🇱

Hematolpgical department Tel Aviv Medical Center, Tel-Aviv, Israel

Stem Cell Transplantation for Patients With Cancers of the Blood

Phase 2
Completed
Conditions
CLL (Chronic Lymphocytic Leukemia)
AML (Acute Myelogenous Leukemia)
CML (Chronic Myelogenous Leukemia)
Acute Lymphocytic Leukemia
MDS (Myelodysplastic Syndrome)
Interventions
Combination Product: Miltenyi system
First Posted Date
2007-05-01
Last Posted Date
2018-07-13
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
61
Registration Number
NCT00467961
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath